ARMP Stock Catalyst: Armata Pharmaceuticals Announces Positive Topline Results from Phase 1B/2A Disarm Trial

May 19, 2025 · 1:41pm ET

Company evaluates AP-SA02 for Staphylococcus Aureus bacteremia treatment.

Max move

+172.7%

High of day $3.19

Sparker timei

1:41pm ET

ARMP · May 19, 2025

CATALYST DATE · 1-MINUTE BARS

Catalyst Summary

Armata Pharmaceuticals, Inc. (ARMP) announced positive topline results from its Phase 1B/2A Disarm trial. The trial evaluated AP-SA02, a novel intravenous multi-phage therapeutic, for the treatment of Staphylococcus Aureus bacteremia in the intent-to-treat population.

The announcement was made following the completion of the trial, with positive outcomes observed. The company did not provide specific numerical data or comparisons in the announcement.

This summary was generated by AI from public sources and may contain errors. Not financial advice. Trade at your own risk.

Real-time alerts

Get notified the next time ARMP sparks.

Download Sniper App →

Catch the next ARMP-style move in real time.

Day Trader Sniper alerts you the moment a setup like this triggers: premarket, open, or intraday.

Watch demo Download Free →